Pfizer has partnered with molecular information firm Foundation Medicine to develop and commercialise companion diagnostics (CDx) for its oncology portfolio.

The new diagnostics will be added as updates to FoundationOne CDx, which is a comprehensive genomic profiling (CGP) assay comprising various companion diagnostics.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

FoundationOne is said to analyse all types of genomic alterations in 324 genes that are known to be associated with cancer growth, as well as genomic biomarkers that could predict the use of immunotherapies.

It is approved by the US Food and Drug Administration (FDA) for all solid tumours and as a broad companion diagnostic for certain types of non-small cell lung, melanoma, colorectal, ovarian, and breast cancers to identify patients who can benefit from using one of 17 on-label targeted therapies.

Under the collaboration, Pfizer will also have access to Foundation Medicine’s data analytics platform called FoundationInsights designed to enable discovery of new biomarkers and optimise clinical trial design.

“We are proud to partner with Pfizer who shares our commitment to precision oncology and biomarker-driven drug development.”

FoundationOne and FoundationInsights are expected to allow Pfizer to use Foundation Medicine’s platform technology to advance discovery and development of precision oncology therapies.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Foundation Medicine biopharma chief business officer and head Melanie Nallicheri said: “We are proud to partner with Pfizer who shares our commitment to precision oncology and biomarker-driven drug development.

“The combination of our FDA-approved comprehensive genomic profiling platform and molecular information solutions, coupled with Pfizer’s robust oncology portfolio, enables us to enhance the impact of precision oncology to advance patient care.”

Pfizer’s existing oncology portfolio includes ten FDA-approved medicines for various types of solid tumours and hematologic malignancies.

The firm also has a pipeline of 17 candidates in clinical development and 19 Phase III trials.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Awarded for Innovation in Remote Hearing Diagnostics , hearX’s Self Test Kit (STK) delivers clinically validated audiometry via smart devices, enabling remote, scalable hearing assessments in homes, clinics and retail. Learn how hearX is redefining hearing care delivery and reducing costs for providers globally.

Discover the Impact